Madrigal Pharmaceuticals Stock News

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohe

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepa

Madrigal Pharmaceuticals (MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The…

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) price on Friday, February 11, fall -3.22% below its previous days close as a downside momentum from buyers pushed the stocks value to $87.37. A look at the stocks price movement, the close in the last trading session was $90.28, moving within a range at $86.60 and $92.45. The beta value Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Fell -3.22%, Now What? Dont Panic Read More »

Madrigal Pharmaceuticals Inc (MDGL) shares closed this week 36.6% higher than it did at the end of last week. The stock is currently up 6.5% year-to-date, down 26.4% over the past 12 months, and up 468.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $95.29 and as low as $66.23 this week.Trading volume this week was 20.0% higher than the 10-day average and 35.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -138.8% The company's stock price performance over the past 12 months beats the peer average by -21.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Madrigal Pharmaceuticals Inc (MDGL) shares closed this week 25.1% higher than it did at the end of last week. The stock is currently down 16.7% year-to-date, down 37.1% over the past 12 months, and up 345.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Shares traded as high as $72.68 and as low as $54.34 this week.Shares closed 50.5% below its 52-week high and 34.9% above its 52-week low.Trading volume this week was 21.9% lower than the 10-day average and 27.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 10.7% higher than its 5-day moving average, 3.5% higher than its 20-day moving average, and 10.8% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8.1% The company's stock price performance over the past 12 months lags the peer average by 19.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

After seeing a sell-off for most of January, two market indexes rose for the fourth day in a row on Wednesday. The S&P 500 Index was up 13.95 points, or 0.31%, while the tech-heavy Nasdaq Composite ga

Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50% reduction liver fat. Key study wi

A positive data readout from a phase 3 clinical trial propelled the drugmaker's shares higher.

Madrigal Pharmaceuticals MDGL +15% liver disease candidate improved key patient outcomes in late-stage study.Yoshitsu Co (TKLF) +14%

A positive data readout from a phase 3 clinical trial propelled the drugmaker's shares higher.

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom:

Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.